The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Open accessAbstract
Background: Current guidelines target low-density lipoprotein cholesterol (LDL-C) concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet clinical trials demonstrate persistent residual ASCVD risk despite aggressive LDL-C lowering. Content: Non–LDL-C lipid parameters, most notably triglycerides, triglyceride-rich lipoproteins (TGRLs), and lipoprotein(a), and C-reactive protein as a measure of inflammation are increasingly recognized as associated with residual risk after LDL-C lowering. Eicosapentaenoic acid in statin-treated patients with high triglycerides reduced both triglycerides and ASCVD events. Reducing TGRLs is believed to have beneficial effects on inflammation and atherosclerosis. High lipoprotein(a) concentrations increase ASCVD risk even in individuals with LDL-C < 70 mg/dL. Although statins do not generally lower lipoprotein(a), proprotein convertase subtilisin/kexin type 9 inhibitors reduce lipoprotein(a) and cardiovascular outcomes, and newer approaches are in development. Persistent increases in C-reactive protein after intensive lipid therapy have been consistently associated with increased risk for ASCVD events. Summary: We review the evidence that biochemical assays to measure TGRLs, lipoprotein(a), and C-reactive protein are associated with residual risk in patients treated to low concentrations of LDL-C. Growing evidence supports a causal role for TGRLs, lipoprotein(a), and inflammation in ASCVD; novel therapies that target TGRLs, lipoprotein(a), and inflammation are in development to reduce residual ASCVD risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,372
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 1×
“Lp(a) concentrations are primarily determined by genetics, and the ability to combine genomic data with epidemiologic data in Mendelian randomization studies has provided evidence that increased concentrations of Lp(a) are causally related to both ASCVD and aortic stenosis (55, 56).”
Background(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094 · cited 1×
“Dose-dependent and sustained Lp(a) reductions of up to 80% were observed in a phase 2 clinical trial, in which the agent was well tolerated, with the major side effect being increased frequency of injection-site erythema reported in those receiving drug compared with placebo (65).”
BackgroundLipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984 · cited 1×
“In patients with higher baseline Lp(a), PCSK9 inhibitor provided greater absolute Lp(a) reduction and greater absolute risk reduction for cardiovascular events (63, 64).”
BackgroundRidker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
Self-citationMartin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Common variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862 · cited 1×
“Genetic studies provide additional evidence of the association of TGRL with ASCVD (33).”
Varbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 14×
“SUMMARY: We review the evidence that biochemical assays to measure TGRLs, lipoprotein(a), and C-reactive protein are associated with residual risk in patients treated to low concentrations of LDL-C.”
BackgroundInfluentialC Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism
Soininen, P., Kangas, A. J., Würtz, P., Tukiainen, T., Tynkkynen, T., Laatikainen, R., Järvelin, M.-R., Kähönen, M., Lehtimäki, T., Viikari, J., et al. (2009) · The Analyst · doi:10.1039/b910205a · Cited by 589
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.057 · Cited by 572
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
Hoogeveen, R. C., Gaubatz, J. W., Sun, W., Dodge, R. C., Crosby, J. R., Jiang, J., Couper, D., Virani, S. S., Kathiresan, S., Boerwinkle, E., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303284 · Cited by 507
Self-citationTsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
ANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467 · cited 1×
“Loss-of-function variants in ANGPTL3 have been associated with decreased TG and LDL-C concentrations and reduced ASCVD risk (41).”
BackgroundKhera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461 · cited 2×
“Statin therapy has been shown to reduce ASCVD events in patients with high concentrations of Lp(a) in both primary and secondary prevention studies (52, 61).”
BackgroundMartin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428 · cited 1×
“Calculated RC is a more accurate estimate if directly measured LDL-C is used instead of LDL-C calculated based upon the Friedewald equation, as the Friedewald equation becomes unreliable when TG concentrations are 400 mg/dL or higher (14).”
MethodCromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 425
Nakajima, K., Saito, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 416
Bergmark, C., Dewan, A., Orsoni, A., Merki, E., Miller, E. R., Shin, M.-J., Binder, C. J., Hörkkö, S., Krauss, R. M., Chapman, M. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800174-jlr200 · Cited by 407
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 339
Duran, E. K., Aday, A. W., Cook, N. R., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.059 · Cited by 334
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315 · cited 1×
“In a post hoc analysis of 10 major statin trials (68) and a prospective analysis the JUPITER study, the greatest benefit of therapy was observed in those who achieved the lowest concentrations of LDL-C and hsCRP (69).”
MethodNägele, U., Hägele, E. O., Sauer, G., Wiedemann, E., Lehmann, P., Wahlefeld, A. W., & Gruber, W. (1984) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.1984.22.2.165 · Cited by 313
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.023 · Cited by 284
Inflammatory and Cholesterol Risk in the FOURIER Trial
Bohula, E. A., Giugliano, R. P., Leiter, L. A., Verma, S., Park, J.-G., Sever, P. S., Lira Pineda, A., Honarpour, N., Wang, H., Murphy, S. A., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034032 · Cited by 280
Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260 · cited 1×
“, a fixed factor for the TG-to-VLDL-C ratio in mg/dL) when Friedewald-estimated LDL-C is used, and in this case it does not add clinical information beyond TG concentration (15).”
MethodHEART UK consensus statement on Lipoprotein(a): A call to action
Cegla, J., Neely, R. D. G., France, M., Ferns, G., Byrne, C. D., Halcox, J., Datta, D., Capps, N., Shoulders, C., Qureshi, N., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.011 · Cited by 247
Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 246
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Direct Determination of Lipoprotein Particle Sizes and Concentrations by Ion Mobility Analysis
Caulfield, M. P., Li, S., Lee, G., Blanche, P. J., Salameh, W. A., Benner, W. H., Reitz, R. E., & Krauss, R. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.100586 · Cited by 227
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211 · cited 1×
“Recently, the multidisciplinary consensus panel of the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine published their recommendations on the quantification of atherogenic lipoproteins beyond LDL-C for lipid-lowering strategies (6).”
BackgroundAssociation of rare and common variation in the lipoprotein lipase gene with coronary artery disease
Khera, A. V., Won, H.-H., Peloso, G. M., O’Dushlaine, C., Liu, D., Stitziel, N. O., Natarajan, P., Nomura, A., Emdin, C. A., Gupta, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.0972 · Cited by 198 · cited 10×
“In a study of older ARIC participants (mean age 76 years, half of whom were taking statin therapy, LDL-TG and RLP-C, markers of TGRL, were associated with TG, and higher LDL-TG concentration was associated with higher risk for CHD and ASCVD independent of traditional risk factors, indicating a role of LDL-TG in residu…”
BackgroundInfluentialHepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender and diet.
Deeb, S. S., Zambon, A., Carr, M. C., Ayyobi, A. F., & Brunzell, J. D. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200017-jlr200 · Cited by 193
Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives
Chapman, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00156-4 · Cited by 180
Joshi, P. H., Khokhar, A. A., Massaro, J. M., Lirette, S. T., Griswold, M. E., Martin, S. S., Blaha, M. J., Kulkarni, K. R., Correa, A., D'Agostino, R. B., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002765 · Cited by 177 · cited 3×
“In a biracial cohort from the Jackson Heart Study and Framingham Offspring Cohort Study, RLP-C was positively associated with incident CHD in unadjusted models (9).”
BackgroundMethodSaeed, A., Feofanova, E. V., Yu, B., Sun, W., Virani, S. S., Nambi, V., Coresh, J., Guild, C. S., Boerwinkle, E., Ballantyne, C. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.050 · Cited by 176
Self-citationMärz, W., Scharnagl, H., Winkler, K., Tiran, A., Nauck, M., Boehm, B. O., & Winkelmann, B. R. (2004) · Circulation · doi:10.1161/01.cir.0000146898.06923.80 · Cited by 161
Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200407000-00019 · Cited by 159
A New Serum Type System in Man — The Ld System
Berg, K. (1965) · Vox Sanguinis · doi:10.1111/j.1423-0410.1965.tb01404.x · Cited by 155
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
Lupton, J. R., Faridi, K. F., Martin, S. S., Sharma, S., Kulkarni, K. R., Jones, S. R., & Michos, E. D. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.09.006 · Cited by 138
Andersen, R. V., Wittrup, H. H., Tybjærg‐Hansen, A., Steffensen, R., Schnohr, P., & Nordestgaard, B. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00407-8 · Cited by 127
Puri, R., Nissen, S. E., Arsenault, B. J., John, J. S., Riesmeyer, J. S., Ruotolo, G., McErlean, E. S., Menon, V., Cho, L., Wolski, K., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2413 · Cited by 123
Williams, P. T., Zhao, X.-Q., Marcovina, S. M., Otvos, J. D., Brown, B. G., & Krauss, R. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.034 · Cited by 105
Albers, J. J., Slee, A. E., Fleg, J. L., O’Brien, K. D., & Marcovina, S. M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.019 · Cited by 96
Balling, M., Nordestgaard, B. G., Langsted, A., Varbo, A., Kamstrup, P. R., & Afzal, S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.072 · Cited by 73 · cited 1×
“The Copenhagen General Population Study recently showed that individuals with high concentrations of small dense LDL-C had higher risks for myocardial infarction (MI) and ASCVD (31).”
BackgroundBalling, M., Langsted, A., Afzal, S., Varbo, A., Smith, G. D., & Nordestgaard, B. G. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.011 · Cited by 73
Dugani, S. B., Akinkuolie, A. O., Paynter, N. P., Glynn, R. J., Ridker, P. M., & Mora, S. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0096 · Cited by 70
Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.005 · Cited by 52
Self-citationSilbernagel, G., Scharnagl, H., Kleber, M. E., Delgado, G., Stojaković, T., Laaksonen, R., Erdmann, J., Rankinen, T., Bouchard, C., Landmesser, U., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.024 · Cited by 49
Bentley, A. R., Chen, G., Shriner, D., Doumatey, A. P., Zhou, J., Huang, H., Mullikin, J. C., Blakesley, R. W., Hansen, N. F., Bouffard, G. G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004190 · Cited by 43
Development and Population Results of a Fully Automated Homogeneous Assay for LDL Triglyceride
Ito, Y., Ohta, M., Ikezaki, H., et al. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2017.024554 · Cited by 30
Development of a Novel Homogeneous Assay for Remnant Lipoprotein Particle Cholesterol
Hirao, Y., Nakajima, K., Machida, T., Murakami, M., & Ito, Y. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2017.024919 · Cited by 22
Watts, G. F., Schwabe, C., Scott, R. S., Gladding, P. A., SULLIVAN, D. R., Baker, J., Clifton, P. M., Hamilton, J., Given, B. D., Melquist, S., et al. (2019) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 18
Self-citation
Cited by
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines
Bornfeldt, K. E. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147558 · Cited by 58
Chen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
“In addition to TRLs, the enduring risk of ASCVD may be linked to elevated levels of lipoprotein (a) (Lp(a)) and chronic inflammation [59].”
Background
Metadata
- Authors
- Hoogeveen, R. C., & Ballantyne, C. M.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-30
- Volume
- 67
- Issue
- 1
- Pages
- 143-153
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W3106601080
- Cited by
- 307
- References
- 80
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.